Familial Mediterranean fever-A review

被引:129
作者
Shohat, Mordechai [1 ,2 ,3 ]
Halpern, Gabrielle J. [1 ,2 ]
机构
[1] Beilinson Med Ctr, Rabin Med Ctr, Raphael Recanati Genet Inst, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
familial Mediterranean fever; mutation; pyrin; proteinuria; amyloidosis; colchicine; MEFV GENE-MUTATIONS; PHENOTYPE-GENOTYPE CORRELATION; INFLAMMATORY-BOWEL-DISEASE; RECURRENT PERICARDITIS; PULMONARY AMYLOIDOSIS; MOLECULAR ANALYSIS; RENAL AMYLOIDOSIS; EGYPTIAN PATIENTS; CLINICAL-DISEASE; CROHNS-DISEASE;
D O I
10.1097/GIM.0b013e3182060456
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial Mediterranean fever is inherited in an autosomal recessive manner. There are two phenotypes: types 1 and 2. Familial Mediterranean fever type 1 is characterized by recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, and, rarely, pericarditis. The symptoms and severity vary among affected individuals, sometimes even among members of the same family. Amyloidosis, which can lead to renal failure, is the most severe complication. Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual. Routine treatment of end-stage renal disease, including renal transplantation, is advised. Lifelong treatment with colchicine is required for homozygotes for the p.Met694Val mutation or compound heterozygotes for p.Met694Val and another disease-causing allele; this prevents the inflammatory attacks and the deposition of amyloid. Individuals who do not have the p.Met694Val mutation and who are only mildly affected should be either treated with colchicine or monitored every 6 months for the presence of proteinuria. Molecular genetic testing of the MEFV gene, the only gene currently known to be associated with familial Mediterranean fever, can be offered to family members, especially when the p.Met694Val allele is present, because renal amyloidosis can be prevented by colchicine. Genet Med 2011: 13(6): 487-498.
引用
收藏
页码:487 / 498
页数:12
相关论文
共 142 条
[1]   Serum amyloid A1 and tumor necrosis factor-alpha alleles in Turkish Familial Mediterranean Fever patients with and without amyloidosis [J].
Akar, N ;
Hasipek, M ;
Akar, E ;
Ekim, M ;
Yalçinkaya, F ;
Çakar, N .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2003, 10 (01) :12-16
[2]  
Akar N, 2006, J NEPHROL, V19, P318
[3]   Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population [J].
Aksentijevich, I ;
Torosyan, Y ;
Samuels, J ;
Centola, M ;
Pras, E ;
Chae, JJ ;
Oddoux, C ;
Wood, G ;
Azzaro, MP ;
Palumbo, G ;
Giustolisi, R ;
Pras, M ;
Ostrer, H ;
Kastner, DL .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 64 (04) :949-962
[4]  
Aksentijevich I, 1997, CELL, V90, P797
[5]  
Alonso R, 2002, J INVEST ALLERG CLIN, V12, P60
[6]   Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever [J].
Alpay, Nilufer ;
Sumnu, Abdullah ;
Caliskan, Yasar ;
Yazici, Halil ;
Turkmen, Aydin ;
Gul, Ahmet .
RHEUMATOLOGY INTERNATIONAL, 2012, 32 (10) :3277-3279
[7]   Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard® -: a standardized fixed combination of Andrographis pankulata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever [J].
Amaryan, G ;
Astvatsatryan, V ;
Gabrielyan, E ;
Panossian, A ;
Panosyan, V ;
Wikman, G .
PHYTOMEDICINE, 2003, 10 (04) :271-285
[8]   MEFV mutations in systemic onset juvenile idiopathic arthritis [J].
Ayaz, N. A. ;
Ozen, S. ;
Bilginer, Y. ;
Erguven, M. ;
Taskiran, E. ;
Yilmaz, E. ;
Besbas, N. ;
Topaloglu, R. ;
Bakkaloglu, A. .
RHEUMATOLOGY, 2009, 48 (01) :23-25
[9]   Molecular analysis of MEFV gene mutations among Palestinian patients with Behcet's disease [J].
Ayesh, S. ;
Abu-Rmaileh, H. ;
Nassar, S. ;
Al-Shareef, W. ;
Abu-Libdeh, B. ;
Muhanna, A. ;
Al-Kafri, F. .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 (05) :370-374
[10]  
Ayesh SK, 2005, SAUDI MED J, V26, P732